{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:07:50Z","timestamp":1787026070102,"version":"build-2736575974"},"reference-count":47,"publisher":"Korean Pediatric Society","issue":"9","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["e-cep.org"],"crossmark-restriction":true},"short-container-title":["Clin Exp Pediatr"],"published-print":{"date-parts":[[2024,9,15]]},"abstract":"<jats:p>Asthma, the most common chronic disease, is characterized by airway in\ufb02ammation and air\ufb02ow obstruction. The World Health Organization estimates that approximately 300 million people worldwide have asthma, 30% of whom are pediatric patients. Asthma is a major cause of morbidity that can lead to hospitalization or death in severe pediatric cases. Therefore, it is necessary to provide children with objective and reliable treatment according to consistent guidelines. Several institutes, such as the Global Institute for Asthma, National Heart, Lung, and Blood Institute, British Thoracic Society, Japanese Society of Pediatric Allergy and Clinical Immunology, and Korean Academy of Asthma, Allergy, and Clinical Immunology have published and revised asthma guidelines. However, since recommendations di\ufb00er among them, confusion persists regarding drug therapy for pediatric asthma patients. Additionally, some guidelines have changed significantly in recent years. This review investigated the latest changes in each guideline, compared and analyzed the recommendations, and identified the international trends in pediatric asthma drug therapy. The findings of this review may aid determinations of the future direction of the Korean guidelines for childhood asthma.<\/jats:p>","DOI":"10.3345\/cep.2022.01466","type":"journal-article","created":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T19:13:07Z","timestamp":1724267587000},"page":"447-455","update-policy":"https:\/\/doi.org\/10.3345\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison and review of international guidelines for treating asthma in children"],"prefix":"10.3345","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5431-5866","authenticated-orcid":true,"given":"Eui Jeong","family":"Roh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1897","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202109-2205pp"},{"key":"ref2","first-page":"1204","volume-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","year":"2020"},{"key":"ref3","volume-title":"Asthma [Internet]","year":"2024"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2004.00526.x"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.5334\/aogh.2416"},{"key":"ref6","first-page":"1225","volume-title":"Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee","year":"1998"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.070169"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2008.106609"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5124\/jkma.2011.54.7.769"},{"key":"ref10","volume-title":"Statistics for disease subclassification (4th level morbidity)[Internet]","year":"2024"},{"key":"ref11","volume-title":"Number of deaths by cause of death [Internet]","year":"2023"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106306"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2016.8.3.223"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2018.11.007"},{"key":"ref15","volume-title":"2020 Focused updates to the asthma management guidelines [Internet]","year":"2020"},{"key":"ref16","volume-title":"BTS\/SIGN British Guideline on the Management of Asthma [Internet]","year":"2019"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2022.07.007"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04173-2020"},{"key":"ref19","volume-title":""},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1715274"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1901963"},{"key":"ref22","first-page":"650","volume-title":"Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial","author":"Martinez","year":"2011"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1378\/chest.130.6.1733"},{"key":"ref24","volume-title":"Management and prevention (2022 update) [Internet]"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2034975"},{"key":"ref26","first-page":"2230","volume-title":"Dupilumab in children with uncontrolled moderate- to severe asthma","author":"Bacharier","year":"2021"},{"key":"ref27","volume-title":"Management and prevention (2023 update) [Internet]"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2203163"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd010834.pub4"},{"key":"ref30","first-page":"69","volume-title":"Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomized phase 3A trial","author":"Lee","year":"2021"},{"key":"ref31","first-page":"i1","volume-title":"British guideline on the management of asthma","year":"2003"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcrj.2006.09.002"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01872-2019"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/nejm200008033430504"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.57.10.880"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016688"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/18.2.223"},{"key":"ref38","volume-title":"Pharmacological management of asthma. Evidence table 4.4a: inhaled corticosteroid vs theophylline","year":"2002"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd003558"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd004108.pub2"},{"key":"ref41","first-page":"CD002173","volume-title":"Inhaled sodium cromoglycate for asthma in children","author":"van der Wouden","year":"2008"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd011721"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd001186.pub2"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1997.tb01172.x"},{"key":"ref45","first-page":"CD011293","volume-title":"Sublingual immunotherapy or asthma","author":"Normansell","year":"2015"},{"key":"ref46","first-page":"360","volume-title":"Montelukast, compared with fluticazone, for control of asthma among 6 to 14 year old patient with mild asthma: the MOSAIC study","author":"Garcia Garcia","year":"2005"},{"key":"ref47","first-page":"879","volume-title":"The use of a patch formulation of tulobuterol, a long acting beta2-adrenoreceptor agonist, in the treatment of severe pediatric asthma","author":"Yosihara","year":"2006"}],"container-title":["Clinical and Experimental Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-cep.org\/upload\/pdf\/cep-2022-01466.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-cep.org\/journal\/view.php?doi=10.3345\/cep.2022.01466","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-cep.org\/upload\/pdf\/cep-2022-01466.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T21:32:03Z","timestamp":1725226323000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-cep.org\/journal\/view.php?doi=10.3345\/cep.2022.01466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,15]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"URL":"https:\/\/doi.org\/10.3345\/cep.2022.01466","relation":{},"ISSN":["2713-4148"],"issn-type":[{"value":"2713-4148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,15]]},"assertion":[{"value":"2022-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-20","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}